由于获得的C1抑制剂缺乏症而引起的血管的deucrictibant:一个随机对照试验
Remy S Petersen1, Lauré M Fijen1, Johannes P Kelder1
1Amsterdam University Medical Center, Department of Vascular Medicine, Amsterdam, and Cardiovascular Sciences, University of Amsterdam, Amsterdam, The Netherlands.
德乌克里克提班在治疗和预防由获得的C1抑制剂缺乏引起的罕见血管发作方面表现有前途. 这种布拉迪基宁B2受体对抗剂在一项小型研究中表明,攻击的严重程度和频率降低了.
科学领域:
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
- 罕见疾病 罕见疾病
背景情况:
- 获得的C1抑制剂缺乏导致罕见的,严重的血管,没有经批准的治疗方法.
- 德乌克里克提班是布拉迪基宁B2受体对抗剂,目前正在研究遗传性血管炎.
研究的目的:
- 评估deucrictibant在获得的C1抑制剂缺乏症中急性和预防性治疗血管的疗效和安全性.
主要方法:
- 一个双部分的,随机的,双盲的,安慰剂控制的交叉研究.
- 第1部分:治疗了4次血管发 edem 发作用deucrictibant (10,20,30毫克) 或安慰剂.
- 第2部分:每天两次服用德克里克提班 (20 mg) 或安慰剂,持续8周.
主要成果:
- 与安慰剂相比,deucrictibant减少了血管发作的严重程度.
- 每月平均发作率从2.0下降到0.0与deucrictibant治疗.
- 没有报告严重的不良事件;发生了一次轻微事件 (腹痛).
结论:
- 德乌克里克蒂班特显示出在获得的C1抑制剂缺乏症中有效和安全地治疗和预防血管的潜力.
- 进一步的研究可能会确定deucrictibant作为这种情况的治疗选择.
更多相关视频
08:04A Rabbit Model of Aqueous-Deficient Dry Eye Disease Induced by Concanavalin A Injection into the Lacrimal Glands: Application to Drug Efficacy Studies
Published on: January 24, 2020
07:13Author Spotlight: Developing Parmodulins to Target Protease-Activated Receptors for Inflammation Control
Published on: May 24, 2024
相关概念视频
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Antihypertensive Drugs: Direct Renin Inhibitors
Depolarizing Blockers: Pharmocokinetics
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
